|Title||Serine Catabolism Regulates Mitochondrial Redox Control during Hypoxia.|
|Publication Type||Journal Article|
|Year of Publication||2014|
|Authors||Ye, J, Fan, J, Venneti, S, Wan, Y-W, Pawel, BR, Zhang, J, Finley, LWS, Lu, C, Lindsten, T, Cross, JR, Qing, G, Liu, Z, M Simon, C, Rabinowitz, JD, Thompson, CB|
|Date Published||2014 Dec|
UNLABELLED: The de novo synthesis of the nonessential amino acid serine is often upregulated in cancer. In this study, we demonstrate that the serine catabolic enzyme, mitochondrial serine hydroxymethyltransferase (SHMT2), is induced when MYC-transformed cells are subjected to hypoxia. In mitochondria, SHMT2 can initiate the degradation of serine to CO2 and NH4 (+), resulting in net production of NADPH from NADP(+). Knockdown of SHMT2 in MYC-dependent cells reduced cellular NADPH:NADP(+) ratio, increased cellular reactive oxygen species, and triggered hypoxia-induced cell death. In vivo, SHMT2 suppression led to impaired tumor growth. In MYC-amplified neuroblastoma patient samples, there was a significant correlation between SHMT2 and hypoxia-inducible factor-1 α (HIF1α), and SHMT2 expression correlated with unfavorable patient prognosis. Together, these data demonstrate that mitochondrial serine catabolism supports tumor growth by maintaining mitochondrial redox balance and cell survival.
SIGNIFICANCE: In this study, we demonstrate that the mitochondrial enzyme SHMT2 is induced upon hypoxic stress and is critical for maintaining NADPH production and redox balance to support tumor cell survival and growth. Cancer Discov; 4(12); 1406-17. ©2014 AACR. See related commentary by Martínez-Reyes and Chandel, p. 1371 This article is highlighted in the In This Issue feature, p. 1355.
|Alternate Journal||Cancer Discov|